Sweden, Denmark Pause Use Of Moderna COVID-19 Shot In Younger Individuals: What You Need To Know - Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

Moderna Inc MRNA stock fell on the back of Sweden, pausing use of its COVID-19 vaccine, Reuters reported citing reports of possible rare side effects such as myocarditis.
The Swedish health agency said that the country would stop using Moderna's shot for people born in 1991 and later.
The health agency said data pointed to increased myocarditis and pericarditis among vaccinated youths and young adults.
Related: EMA Says Heart Inflammation Likely Linked To mRNA-Based COVID-19 Vaccines.
"The connection is especially clear when it comes to Moderna's vaccine Spikevax, especially after the second dose," it said in a statement," adding the risk of being affected was very small.
The health agency now recommended the Comirnaty vaccine from Pfizer Inc PFE / BioNTech SE BNTX instead.
The Swedish health agency said people aged 12-15 would only get the Pfizer / BioNTech vaccine earlier this week.
Related: Moderna's COVID-19 Booster Ok'd In Europe For Immunocompromised.
Denmark said that, while it used the Pfizer/BioNTech vaccine as its main option for people aged 12-17 years, it had decided to pause vaccination with Moderna shot to people below 18 according to a "precautionary principle."
"In the preliminary data ... there is a suspicion of an increased risk of heart inflammation when vaccinated with Moderna," the Danish Health Authority said in a statement.
Related: Is Moderna's COVID-19 Booster Shot Moving Closer To Authorization?
Price Action: MRNA stock is down 5.95% at $312.36 during the market session on the last check Wednesday.
Photo by Spencer Davis from Pixabay

Market News and Data brought to you by Benzinga APIs